In vivo, systemic administration of LRP5-overexpressing osteocyte-derived conditioned medium reduced mammary tumor burden and mitigated osteolytic bone destruction in tibial metastasis, whereas genetic disruption of LIMA1 in osteocytes or MYO5B in tumor cells abrogated these protective effects. This evidence concerns the gene LRP5 and breast cancer.